Company / Return on Equity (ROE)
ClearPoint Neuro, Inc. Return on Equity (ROE) History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-91.1%
FY2025
5-year range
-104.3% / -29.5%
FY2021-FY2025
Trend
+12.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
ClearPoint Neuro, Inc. reports negative total equity of -91.1% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-91.1% in FY2025 with a 5-year CAGR of +194.2%.
Improved from -104.3% to -91.1% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -46.6pp
- 5-Year Change
- +194.2pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, return on equity (roe) increased 12.6% year-over-year.
- Peak return on equity (roe) was recorded in FY2021.
- Lowest return on equity (roe) in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score -1.71 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -91.1% | +12.6% |
| FY2024 | -104.3% | +0.0% |
| FY2023 | -104.3% | -134.2% |
| FY2022 | -44.5% | -50.8% |
| FY2021 | -29.5% | +89.6% |
| FY2020 | -285.3% | -136.2% |
| FY2019 | -120.8% | +70.4% |
| FY2018 | -408.2% | -231.9% |
| FY2017 | -123.0% | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026